12/6/2007

An FDA advisory panel voted 5-4 Wednesday against approving Genentech's cancer drug Avastin as a first-line treatment for patients with recurrent or metastatic breast cancer. A National Cancer Institute study showed no significant difference in overall survival for patients who took Avastin with Taxol compared to those taking Taxol alone.

Related Summaries